LILRB5 Antibody
-
中文名稱：LILRB5兔多克隆抗體
-
貨號：CSB-PA012943GA01HU
-
規(guī)格：￥3,900
-
其他：
產(chǎn)品詳情
-
Uniprot No.：
-
基因名：
-
別名：LILRB5; LIR8; Leukocyte immunoglobulin-like receptor subfamily B member 5; CD85 antigen-like family member C; Leukocyte immunoglobulin-like receptor 8; LIR-8; CD antigen CD85c
-
宿主：Rabbit
-
反應種屬：Human
-
免疫原：Human LILRB5
-
免疫原種屬：Homo sapiens (Human)
-
抗體亞型：IgG
-
純化方式：Antigen Affinity Purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
-
產(chǎn)品提供形式：Liquid
-
應用范圍：ELISA,WB
-
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情
-
功能：May act as receptor for class I MHC antigens.
-
基因功能參考文獻：
- The transcriptional profile of the orphan receptor LILRB5 is significantly up-regulated following exposure to mycobacteria. PMID: 26908331
- LILRB5 binding to intracellular HLA-class I heavy chains suggests a chaperone function PMID: 26098415
- The rs12975366 in the LILRB5 gene was significantly associated with CK levels of statin users. PMID: 25214527
- Mature cord-blood-derived mast cells expressed LILRB5 in cytoplasmic granules and upon cross-linking of the high-affinity IgE receptor, released LILRB5 into the culture medium. PMID: 17998301
-
亞細胞定位：Membrane; Single-pass type I membrane protein.
-
組織特異性：Detected in a natural killer (NK) cells.
-
數(shù)據(jù)庫鏈接：
Most popular with customers
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-
